Westminster Health Forum

For booking-related queries or information on speaking please email us at info@forumsupport.co.uk, or contact us: +44 (0)1344 864796.

Next steps for the life sciences industry in the UK

Industrial Strategy Sector Plan | medicine pricing & procurement | streamlining regulation | supporting innovation ecosystem | approval pathway efficiency | international competitiveness | attracting investment | workforce development | leveraging regiona

Morning, Wednesday, 15th October 2025

Online


This conference focuses on next steps for genomics in the UK.


It will be an opportunity for stakeholders and policymakers to examine the evolving role of genomics in the shift towards a more preventative and personalised health system, with the 10-Year Health Plan and Life Sciences Sector Plan identifying it as a priority area. Areas for discussion include implications for research, care delivery, population health and system integration.


The agenda explores strategic priorities for embedding genomics in mainstream healthcare, including coordination across the four nations, and timelines for delivering complex services, with the Genome UK: shared commitments for UK-wide implementation 2022-2025 and subsequent implementation plans concluding this year.


System-wide adoption of genomic healthcare
Requirements for enabling a new genomic population health service will be considered, including how integrated care boards and neighbourhood providers can support data-informed commissioning and care provision. Attendees will assess proposals in the Life Sciences Sector Plan, including the role of the new Health Data Research Service and what will be needed to put in place digital, organisational and workforce capabilities required to integrate genomic tools and services across clinical pathways, support research and deliver patient benefit. Strategic considerations for addressing data interoperability and system coordination challenges will also be discussed.


Personalised medicine, whole genome sequencing and implementation
Delegates will consider practical steps toward equitable access to personalised medicine, including the rollout of genomic testing and targeted treatments, and discuss implementation challenges around whole genome sequencing for newborns.


In considering health inequalities and representation in genomics moving forward, delegates will look at priorities for investment in sequencing for people from diverse backgrounds and engagement with communities that have historically been under-represented in genomic research and services, including minoritised ethnic groups, underserved populations, people with disabilities, non-English speakers, and those experiencing socioeconomic disadvantage, to build trust and inclusion.


Building the genomics workforce and NHS readiness
Priorities for expanding the NHS genomics workforce will be discussed, looking at funding and delivery capacity, and tackling shortages of trained professionals, including strategies for supporting nurses to become genomics champions in local communities, and building system-wide readiness for artificial intelligence-supported clinical decision-making based on genomic insights. We also expect a focus on priorities for supporting healthcare professionals to communicate complex results, as well as next steps for standardising whole genome sequencing service delivery processes across the NHS in order to reduce variation and enhance efficiency.  


Consent, privacy, and future regulatory and innovation frameworks
Further sessions focus on approaches to patient consent, privacy, and data use, including the management of actionable findings, secondary data uses, and trust in de-identified datasets. The agenda also explores evolving regulatory frameworks and evidence requirements for test evaluation and commissioning, as well as future options for supporting innovation through collaboration, infrastructure investment, and joined-up research and clinical activity.


All delegates will be able to contribute to the output of the conference, which will be shared with parliamentary, ministerial, departmental and regulatory offices, and more widely. This includes the full proceedings and additional articles submitted by delegates. As well as key stakeholders, those already due to attend include officials from the Department of Health and Social Care; Department of Health, NI; Department for Business and Trade; Office for Health Improvement and Disparities; Office for Life Sciences; Parliamentary Office of Science and Technology; the Welsh Government; and The Scottish Government.



Keynote Speakers

Roland Sinker CBE

Chief Executive, Cambridge University Hospitals NHS Foundation Trust and Cambridge Biomedical Campus; and National Director, Life Sciences, NHS England

Dr Richard Torbett

Chief Executive, Association of the British Pharmaceutical Industry

Dr Andrea Manfrin

Deputy Director, Clinical Investigations and Trials, Medicines and Healthcare products Regulatory Agency

Keynote Speakers

Dr Andrea Manfrin

Deputy Director, Clinical Investigations and Trials, Medicines and Healthcare products Regulatory Agency

Dr Richard Torbett

Chief Executive, Association of the British Pharmaceutical Industry

Alfred Casson

Design for Life Programme Co-Lead, Research, Systems, and Behaviours, Medical Technologies and Innovation Directorate, Department of Health and Social Care

Jenna Dilkes

Associate Director, Planning and Operations, Medicines Evaluation, National Institute for Health and Care Excellence

Roland Sinker CBE

Chief Executive, Cambridge University Hospitals NHS Foundation Trust and Cambridge Biomedical Campus; and National Director, Life Sciences, NHS England

Chair

Rt Hon Kit Malthouse MP

Member, Science, Innovation and Technology Committee; and Chair, All-Party Parliamentary Group for Life Sciences

Speakers

Dan Jones

Director, Government Affairs, UK and Ireland, Stryker

Helen Dent

Chief Executive, British In Vitro Diagnostics Association

Dr Scott Purdon

Head, Patient Advocacy, Myeloma UK; and Chair, Charity Medicines Access Coalition

Professor Raghib Ali

CEO, Chief Investigator and Chief Medical Officer, Our Future Health

Dr Claire Cole

Deputy Managing Director, Research and Innovation, Manchester University NHS Foundation Trust; and Director, NIHR Greater Manchester Commercial Research Delivery Centre

Jane Lewis

Chief Operating Officer and Chief Financial Officer, Association of British HealthTech Industries

Diane DiGangi Trench

Head, Northern Cluster Europe, Sandoz

Dr Mandy Dixon

Executive Lead, Corporate Engagement and Cluster Development, Northern Health Science Alliance

Richard Sloggett

Founder and Programme Director, Future Health Research